@article{MacedoJavadiHiguchietal.2015, author = {Macedo, Robson and Javadi, Som Mehrbod and Higuchi, Takahiro and Ferreira de Carvalho, Marilia Daniela and Lima Paiva Medeiros, Vanessa de F{\´a}tima and Azevedo, {\´I}talo Medeiros and Lima, Francisco Pignataro and Medeiros, Aldo Cunha}, title = {Heart and systemic effects of statin pretreatment in a rat model of abdominal sepsis. Assessment by Tc\(^{99m}\)-sestamibi biodistribition}, series = {Acta Cir{\´u}rgica Brasileira}, volume = {30}, journal = {Acta Cir{\´u}rgica Brasileira}, number = {6}, doi = {10.1590/S0102-865020150060000003}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-151887}, pages = {388 -- 393}, year = {2015}, abstract = {PURPOSE: To evaluate the heart and the Tc-99m-sestamibi biodistribution after statin pretreatment in a rat model of abdominal sepsis. METHODS: Twenty-four Wistar rats were randomly distributed into four groups (n=6 per group): 1) sepsis with simvastatin treatment, 2) sepsis with vehicle, 3) sham control with simvastatin and 4) sham control with vehicle. 24 hours after cecal ligation and puncture rats received 1.0MBq of Tc-99m-sestamibi i.v. 30min after, animals were euthanized for ex-vivo tissue counting and myocardium histological analysis. RESULTS: Myocardial histologic alterations were not detected 24 hours post-sepsis. There was significantly increased cardiac Tc-99m-sestamibi activity in the sepsis group with simvastatin treatment (1.9\(\pm\)0.3\%ID/g, p<0.001) in comparison to the sepsis group+vehicle (1.0\(\pm\)0.2\% ID/g), control sham group+ simvastatin (1.2\(\pm\)0.3\% ID/g) and control sham group (1.3\(\pm\)0.2\% ID/g). Significant Tc-99m-sestamibi activity in liver, kidney and lungs was also detected in the sepsis group treated with simvastatinin comparison to the other groups. CONCLUSIONS: Statin treatment altered the biodistribution of Tc-99m-sestamibi with increased cardiac and solid organ activity in rats with abdominal sepsis, while no impact on controls. Increased myocardial tracer activity may be a result of a possible protection effect due to increased tissue perfusion mediated by statins.}, language = {en} } @article{IsaiasSpiegelBrumbergetal.2014, author = {Isaias, Ioannis Ugo and Spiegel, J{\"o}rg and Brumberg, Joachim and Cosgrove, Kelly P. and Marotta, Giorgio and Oishi, Naoya and Higuchi, Takahiro and K{\"u}sters, Sebastian and Schiller, Markus and Dillmann, Ulrich and van Dyck, Christopher H. and Buck, Andreas and Herrmann, Ken and Schloegl, Susanne and Volkmann, Jens and Lassmann, Michael and Fassbender, Klaus and Lorenz, Reinhard and Samnick, Samuel}, title = {Nicotinic acetylcholine receptor density in cognitively intact subjects at an early stage of Parkinson's disease}, series = {Frontiers in Aging Neuroscience}, volume = {6}, journal = {Frontiers in Aging Neuroscience}, doi = {10.3389/fnagi.2014.00213}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-119351}, pages = {213}, year = {2014}, abstract = {We investigated in vivo brain nicotinic acetylcholine receptor (nAChR) distribution in cognitively intact subjects with Parkinson's disease (PD) at an early stage of the disease. Fourteen patients and 13 healthy subjects were imaged with single photon emission computed tomography and the radiotracer 5-[(123)I]iodo-3-[2(S)-2-azetidinylmethoxy]pyridine ([(123)I]5IA). Patients were selected according to several criteria, including short duration of motor signs (<7 years) and normal scores at an extensive neuropsychological evaluation. In PD patients, nAChR density was significantly higher in the putamen, the insular cortex and the supplementary motor area and lower in the caudate nucleus, the orbitofrontal cortex, and the middle temporal gyrus. Disease duration positively correlated with nAChR density in the putamen ipsilateral (ρ = 0.56, p < 0.05) but not contralateral (ρ = 0.49, p = 0.07) to the clinically most affected hemibody. We observed, for the first time in vivo, higher nAChR density in brain regions of the motor and limbic basal ganglia circuits of subjects with PD. Our findings support the notion of an up-regulated cholinergic activity at the striatal and possibly cortical level in cognitively intact PD patients at an early stage of disease.}, language = {en} }